Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT07429032 · ClinicalTrials.gov registry record · Phase 1
The Effect of AMG 133 on Gastric Emptying
A Phase 1 study, sponsored by Amgen.
- Completed
- Registry status
- Phase 1
- Development phase
- 57
- Enrollment target
NCT07429032 is a Phase 1 study that has completed, run by Amgen. The registered enrollment target is 57 participants.
The verdict
NCT07429032, a Phase 1 study, has completed, sponsored by Amgen.
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 57 participants
- Enrollment target
Study Summary
The primary objective of the trial is to evaluate the effect of AMG 133 versus placebo on acetaminophen pharmacokinetics (PK), a marker for gastric emptying, in participants living with overweight or obesity.
Interventions
- DRUG Placebo
- DRUG Acetaminophen
- DRUG AMG 133
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 57 participants |
| Start Date | 2025-04-17 |
| Est. Completion | 2025-11-26 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT07429032
The ClinicalTrials.gov registry entry for NCT07429032 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 57 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Amgen, which has 558 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT07429032 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT07429032 about?
NCT07429032 is a clinical study titled "The Effect of AMG 133 on Gastric Emptying". The primary objective of the trial is to evaluate the effect of AMG 133 versus placebo on acetaminophen pharmacokinetics (PK), a marker for gastric emptying, in participants living with overweight or obesity.
What is the current status of trial NCT07429032?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 57 participants. The study started on 2025-04-17. Estimated completion is 2025-11-26.
What interventions are being tested in trial NCT07429032?
The interventions under investigation include: Placebo (DRUG), Acetaminophen (DRUG), AMG 133 (DRUG).
Who is sponsoring clinical trial NCT07429032?
This trial is sponsored by Amgen, which has 558 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.